Why is Neuronetics, Inc. ?
- The company has declared positive results in Jan 70 after 4 consecutive negative quarters
- NET PROFIT(HY) Higher at USD -19.16 MM
- NET SALES(Q) At USD 37.3 MM has Grown at 101.28%
- INVENTORY TURNOVER RATIO(HY) Highest at 14.55 times
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -70.65%, its profits have fallen by -37.8%
- Promoters have increased their stake in the company by 27.94% over the previous quarter and currently hold 27.94% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
- Even though the market (S&P 500) has generated returns of 14.90% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -70.65% returns
How much should you hold?
- Overall Portfolio exposure to Neuronetics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Neuronetics, Inc. for you?
High Risk, Low Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Higher at USD -19.16 MM
At USD 37.3 MM has Grown at 101.28%
Highest at 14.55 times
Highest at 6.75 times
Highest at USD -6.43 MM
Highest at -17.25 %
Highest at USD -0.13
Lowest at -239.53%
Grown by 40.82% (YoY
Lowest at USD 52.29 MM
Highest at USD 2.21 MM
Here's what is working for Neuronetics, Inc.
Net Sales (USD MM)
Net Profit (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
EPS (USD)
Inventory Turnover Ratio
Debtors Turnover Ratio
Here's what is not working for Neuronetics, Inc.
Interest Paid (USD MM)
Interest Paid (USD MM)
Cash and Cash Equivalents
Raw Material Cost as a percentage of Sales






